SOAT1 and schizophrenia: Our research hypothesis is that atypical antipsychotic risperidone, similar to minocycline, inhibits the activation of microglia through the MAPK, and JAK-STAT signaling pathways, thereby exerting a therapeutic effect on the negative symptoms of schizophrenia.